Brokerages expect Castle Biosciences, Inc. (NASDAQ:CSTL) to report sales of $23.43 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Castle Biosciences’ earnings. The highest sales estimate is $23.45 million and the lowest is $23.40 million. Castle Biosciences reported sales of $17.30 million in the same quarter last year, which would suggest a positive year over year growth rate of 35.4%. The business is expected to report its next quarterly earnings report on Monday, March 14th.
On average, analysts expect that Castle Biosciences will report full-year sales of $92.50 million for the current fiscal year. For the next year, analysts anticipate that the company will report sales of $117.58 million, with estimates ranging from $114.06 million to $121.10 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Castle Biosciences.
Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Sunday, November 7th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.13). Castle Biosciences had a negative net margin of 34.46% and a negative return on equity of 6.76%. During the same period in the previous year, the business posted ($0.23) EPS.
Several equities analysts have recently weighed in on the company. Robert W. Baird raised their price target on Castle Biosciences from $78.00 to $82.00 and gave the company an “outperform” rating in a report on Tuesday, November 9th. SVB Leerink reduced their price target on Castle Biosciences from $85.00 to $75.00 and set an “outperform” rating for the company in a report on Tuesday, November 9th. Zacks Investment Research downgraded Castle Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, November 11th. Finally, Canaccord Genuity raised their price target on Castle Biosciences from $47.00 to $52.00 and gave the company a “buy” rating in a report on Friday, September 3rd. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Castle Biosciences has a consensus rating of “Buy” and an average target price of $78.83.
In other news, insider Derek J. Maetzold sold 2,500 shares of Castle Biosciences stock in a transaction dated Tuesday, November 9th. The stock was sold at an average price of $56.66, for a total transaction of $141,650.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Bernhard E. Spiess sold 15,401 shares of Castle Biosciences stock in a transaction dated Thursday, September 2nd. The shares were sold at an average price of $75.78, for a total value of $1,167,087.78. The disclosure for this sale can be found here. Insiders sold a total of 78,734 shares of company stock valued at $5,330,760 over the last quarter. 39.70% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Castle Biosciences by 3.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,167 shares of the company’s stock valued at $379,000 after buying an additional 160 shares in the last quarter. Valmark Advisers Inc. lifted its position in shares of Castle Biosciences by 2.6% during the 3rd quarter. Valmark Advisers Inc. now owns 9,024 shares of the company’s stock valued at $600,000 after buying an additional 229 shares in the last quarter. Baird Financial Group Inc. lifted its holdings in Castle Biosciences by 1.9% in the 2nd quarter. Baird Financial Group Inc. now owns 12,593 shares of the company’s stock worth $923,000 after purchasing an additional 230 shares in the last quarter. Royal Bank of Canada lifted its holdings in Castle Biosciences by 15.3% in the 2nd quarter. Royal Bank of Canada now owns 1,775 shares of the company’s stock worth $130,000 after purchasing an additional 235 shares in the last quarter. Finally, Great West Life Assurance Co. Can lifted its holdings in Castle Biosciences by 36.0% in the 1st quarter. Great West Life Assurance Co. Can now owns 1,292 shares of the company’s stock worth $88,000 after purchasing an additional 342 shares in the last quarter. 82.84% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:CSTL opened at $41.35 on Tuesday. Castle Biosciences has a 1-year low of $40.90 and a 1-year high of $107.69. The firm’s fifty day moving average is $61.74. The company has a market capitalization of $1.05 billion, a P/E ratio of -33.89 and a beta of 0.47.
Castle Biosciences Company Profile
Castle Biosciences, Inc is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma.
See Also: What is a balanced fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com